SSII · SS Innovations International, Inc.

SS Innovations delivered a materially stronger first quarter in 2026, with revenue more than doubling to $11.1 million — the highest quarterly revenue in company history — driven primarily by 73.3% growth in SSi Mantra system installations (26 units) and a 136.2% increase in quarterly procedures (1,859 surgeries). Gross margin nearly doubled to 48.0%, reflecting favorable product mix (system sales grew 112.7% to $9.6 million), improved manufacturing scale, and reduced per-unit cost absorption. The Company’s strategic focus on emerging markets bore fruit: regulatory approvals were secured in Sri Lanka, Kenya, Indonesia, and the Philippines — including specific telesurgery clearance — enabling broader commercial deployment. A $18.6 million private placement in March 2026 significantly strengthened the balance sheet, lifting unrestricted cash to $16.0 million as of March 31, 2026, while long-term debt remained at zero. Though operating expenses increased — notably SG&A (+32%) and stock compensation (+32%) — the net loss narrowed meaningfully to $3.6 million, or $(0.02) per diluted share, from $5.7 million in Q1 2025. Management highlighted continued progress toward U.S. FDA 510(k) clearance and EU CE marking, both targeted for completion in 2026, underscoring near-term catalysts for geographic expansion and revenue diversification beyond current international markets.